This improvement may be attributed to the synergistic antitumor effects achieved by enhancing tumor cell sensitivity to PD-1 inhibitors through chemotherapy and counteracting the negative immunoregulatory effects induced by chemotherapy.[18] PD-1 inhibitors in combination with chemotherapy were more effective in patients with CPS ≥ 10 and MSI-H. Here, PDCD1 is linked to neoplasm.